DE2748825C2
(de)
*
|
1976-11-02 |
1986-11-27 |
Sankyo Co., Ltd., Tokio/Tokyo |
Substituierte 3,5-Dihydroxyheptansäurederivate und diese enthaltende Arzneimittel gegen Hyperlipämie
|
JPS53147073A
(en)
*
|
1977-05-24 |
1978-12-21 |
Sankyo Co Ltd |
Mevalonolactone derivatives
|
ZA795567B
(en)
*
|
1978-10-19 |
1981-06-24 |
Merck & Co Inc |
Treatment of hypercholesteremia
|
NZ191762A
(en)
*
|
1978-10-19 |
1982-09-14 |
Merck & Co Inc |
Hypocholesteremic composition containing cholesterol synthesis inhibitor and anion exchange resin
|
JPS5559180A
(en)
*
|
1978-10-30 |
1980-05-02 |
Sankyo Co Ltd |
4-hydroxy-2-pyrone ring compound, its preparation, and remedy for hyperlipemia comprising it as active constituent
|
JPS5925599B2
(ja)
|
1979-02-20 |
1984-06-19 |
三共株式会社 |
新生理活性物質モナコリンkおよびその製造法
|
JPS55150898A
(en)
*
|
1979-05-11 |
1980-11-25 |
Sankyo Co Ltd |
Preparation of a new physiologically active substance mb-530b
|
US4319039A
(en)
*
|
1979-06-15 |
1982-03-09 |
Merck & Co., Inc. |
Preparation of ammonium salt of hypocholesteremic fermentation product
|
US4231938A
(en)
*
|
1979-06-15 |
1980-11-04 |
Merck & Co., Inc. |
Hypocholesteremic fermentation products and process of preparation
|
US4294926A
(en)
*
|
1979-06-15 |
1981-10-13 |
Merck & Co., Inc. |
Hypocholesteremic fermentation products and process of preparation
|
US4567289A
(en)
*
|
1979-08-17 |
1986-01-28 |
Merck & Co., Inc. |
Substituted pyranone inhibitors of cholesterol synthesis
|
US4710513A
(en)
*
|
1979-08-17 |
1987-12-01 |
Merck & Co., Inc. |
Substituted pyranone inhibitors of cholesterol synthesis
|
US4459422A
(en)
*
|
1979-08-17 |
1984-07-10 |
Merck & Co., Inc. |
Substituted pyranone inhibitors of cholesterol synthesis
|
US4375475A
(en)
*
|
1979-08-17 |
1983-03-01 |
Merck & Co., Inc. |
Substituted pyranone inhibitors of cholesterol synthesis
|
US4294846A
(en)
*
|
1979-09-21 |
1981-10-13 |
Merck & Co., Inc. |
Hypocholesteremic fermentation products and products of preparation
|
US4293496A
(en)
*
|
1980-02-04 |
1981-10-06 |
Merck & Co., Inc. |
6(R)-[2-(8-Hydroxy-2,6-dimethylpolyhydronaphthyl-1)-ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-ones
|
US4444784A
(en)
*
|
1980-08-05 |
1984-04-24 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
PT72394B
(en)
*
|
1980-02-04 |
1982-09-06 |
Merck & Co Inc |
Process for preparing dihydro and tetrahydromevinoline hypocholesterolimics
|
AU548996B2
(en)
|
1980-02-04 |
1986-01-09 |
Merck & Co., Inc. |
Tetrahydro-2h-pyran-2-one derivatives
|
US4282155A
(en)
*
|
1980-02-04 |
1981-08-04 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
JPH0692381B2
(ja)
*
|
1980-03-31 |
1994-11-16 |
三共株式会社 |
Mb−530a誘導体
|
JPS56142236A
(en)
|
1980-04-08 |
1981-11-06 |
Sankyo Co Ltd |
Ml-236a and mb-530a derivative
|
US4322563A
(en)
*
|
1980-04-14 |
1982-03-30 |
Merck & Co., Inc. |
Substituted biphenyl-2-carboxaldehydes
|
JPS56150037A
(en)
*
|
1980-04-22 |
1981-11-20 |
Sankyo Co Ltd |
Hydronaphthalene compound
|
US4420491A
(en)
*
|
1980-05-28 |
1983-12-13 |
Merck & Co., Inc. |
Hypocholesteremic fermentation products and process of preparation
|
MX7065E
(es)
*
|
1980-06-06 |
1987-04-10 |
Sankyo Co |
Un procedimiento microbiologico para preparar derivados de ml-236b
|
US4450171A
(en)
*
|
1980-08-05 |
1984-05-22 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
US4343814A
(en)
*
|
1980-11-17 |
1982-08-10 |
Merck & Co., Inc. |
Hypocholesterolemic fermentation products
|
US4432996A
(en)
*
|
1980-11-17 |
1984-02-21 |
Merck & Co., Inc. |
Hypocholesterolemic fermentation products and process of preparation
|
JPS57123140A
(en)
*
|
1981-01-23 |
1982-07-31 |
Sankyo Co Ltd |
Ml-236b carboxylic acid amine salt and remedy for hyperlipemia containing said salt as active component
|
JPS5815968A
(ja)
*
|
1981-07-21 |
1983-01-29 |
Sankyo Co Ltd |
Ml−236b誘導体およびその製法
|
US4376863A
(en)
*
|
1981-08-21 |
1983-03-15 |
Merck & Co., Inc. |
Hypocholesterolemic fermentation products
|
US4387242A
(en)
*
|
1981-08-21 |
1983-06-07 |
Merck & Co., Inc. |
Hypocholesterolemic fermentation products and process of preparation
|
JPS5835144A
(ja)
*
|
1981-08-27 |
1983-03-01 |
Sankyo Co Ltd |
Mb−530b誘導体およびその製造法
|
US5354772A
(en)
*
|
1982-11-22 |
1994-10-11 |
Sandoz Pharm. Corp. |
Indole analogs of mevalonolactone and derivatives thereof
|
US4499289A
(en)
*
|
1982-12-03 |
1985-02-12 |
G. D. Searle & Co. |
Octahydronapthalenes
|
US4503072A
(en)
*
|
1982-12-22 |
1985-03-05 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
US4582915A
(en)
*
|
1983-10-11 |
1986-04-15 |
Merck & Co., Inc. |
Process for C-methylation of 2-methylbutyrates
|
US4584389A
(en)
*
|
1983-10-11 |
1986-04-22 |
Merck & Co., Inc. |
Processes for preparing 6(R)-[2-[8(S)(2,2-dimethylbutyryloxy)-2(S),6(S)-dimethyl-1,2,3,4,4a(S),5,6,7,8,8a(S)-decahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one
|
DE3480923D1
(de)
*
|
1983-10-11 |
1990-02-08 |
Merck & Co Inc |
Verfahren zur c-methylierung von 2-methylbutyraten.
|
US4613610A
(en)
*
|
1984-06-22 |
1986-09-23 |
Sandoz Pharmaceuticals Corp. |
Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
|
US4686237A
(en)
*
|
1984-07-24 |
1987-08-11 |
Sandoz Pharmaceuticals Corp. |
Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
|
US4804679A
(en)
*
|
1984-07-24 |
1989-02-14 |
Sandoz Pharm. Corp. |
Erythro-(E)-7-(3'-C1-3alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl)-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
|
US4647576A
(en)
*
|
1984-09-24 |
1987-03-03 |
Warner-Lambert Company |
Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
|
US5001255A
(en)
*
|
1984-12-04 |
1991-03-19 |
Sandoz Pharm. Corp. |
Idene analogs of mevalonolactone and derivatives thereof
|
US4668794A
(en)
*
|
1985-05-22 |
1987-05-26 |
Sandoz Pharm. Corp. |
Intermediate imidazole acrolein analogs
|
US4766145A
(en)
*
|
1986-05-05 |
1988-08-23 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
US4771071A
(en)
*
|
1986-05-05 |
1988-09-13 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
US4847306A
(en)
*
|
1986-05-05 |
1989-07-11 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
US4864038A
(en)
*
|
1986-05-05 |
1989-09-05 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
US4681893A
(en)
*
|
1986-05-30 |
1987-07-21 |
Warner-Lambert Company |
Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
|
US5102893A
(en)
*
|
1986-07-07 |
1992-04-07 |
Warner-Lambert Company |
Trans-6-(2-(n-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl- or ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
|
US4957971A
(en)
*
|
1986-07-07 |
1990-09-18 |
Warner-Lambert Company |
Trans-6-(2-(N-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl)-or ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
|
US4678806A
(en)
*
|
1986-09-02 |
1987-07-07 |
Merck & Co., Inc. |
Prodrugs of antihypercholesterolemic compounds
|
US5091378A
(en)
*
|
1987-05-22 |
1992-02-25 |
E. R. Squibb & Sons, Inc. |
Phosphorus-containing HMG-CoA reductase inhibitors, new intermediates and method
|
US4904646A
(en)
*
|
1987-05-22 |
1990-02-27 |
E. R. Squibb & Sons, Inc. |
Phosphorus-containing HMG-COA reductase inhibitors
|
US4997848A
(en)
*
|
1987-10-27 |
1991-03-05 |
Sankyo Company, Limited |
Octahydronaphthalene oxime derivatives for cholesterol synthesis inhibition
|
US4876280A
(en)
*
|
1988-03-10 |
1989-10-24 |
Sandoz Pharm. Corp. |
Arylcyclohexane and arylcyclohexene analogs of mevalonolactone derivatives and their use
|
US5180589A
(en)
*
|
1988-03-31 |
1993-01-19 |
E. R. Squibb & Sons, Inc. |
Pravastatin pharmaceuatical compositions having good stability
|
US5506219A
(en)
*
|
1988-08-29 |
1996-04-09 |
E. R. Squibb & Sons, Inc. |
Pyridine anchors for HMG-CoA reductase inhibitors
|
US4957940A
(en)
*
|
1988-12-21 |
1990-09-18 |
Warner-Lambert Company |
Bicyclo heptane and bicyclo octane substituted inhibitors of cholesterol synthesis
|
US4906657A
(en)
*
|
1988-12-21 |
1990-03-06 |
Warner-Lambert Company |
Bicyclo heptane and bicyclo octane substituted inhibitors of cholesterol synthesis
|
CA2007641A1
(fr)
*
|
1989-02-01 |
1990-08-01 |
Donald S. Karanewsky |
Combinaison d'un inhibiteur de squalene synthetase et d'autres types d'agents reducteurs du cholesterol sanguin et methode pour abaisser le taux de cholesterol sanguin en employant une telle combinaison
|
US5001148A
(en)
*
|
1989-06-07 |
1991-03-19 |
E. R. Squibb & Sons, Inc. |
Mevinic acid derivatives
|
US4997849A
(en)
*
|
1989-06-23 |
1991-03-05 |
Merck & Co., Inc. |
Microbial transformation of simvastatin
|
FI94339C
(fi)
|
1989-07-21 |
1995-08-25 |
Warner Lambert Co |
Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
|
US5189180A
(en)
*
|
1989-09-28 |
1993-02-23 |
E. R. Squibb & Sons, Inc. |
Seco-mevinic acid derivatives useful as antihypercholesterolemic agents and new intermediates
|
US5025017A
(en)
*
|
1989-09-28 |
1991-06-18 |
E. R. Squibb & Sons, Inc. |
Seco-mevinic acid derivatives useful as antihypercholesterolemic agents and new intermediates
|
US5173487A
(en)
*
|
1989-11-13 |
1992-12-22 |
E. R. Squibb & Sons, Inc. |
Mevinic acid derivatives
|
US5264455A
(en)
*
|
1990-07-06 |
1993-11-23 |
E. R. Squibb & Sons, Inc. |
Sulfur-substituted mevinic acid derivatives
|
WO1992019239A1
(fr)
*
|
1991-05-01 |
1992-11-12 |
University Of New Mexico |
Traitement d'etats cellulaires aberrants a l'aide de biomodulateurs
|
WO1992019240A1
(fr)
*
|
1991-05-01 |
1992-11-12 |
University Of New Mexico |
Traitement d'aberrations cellulaires avec des biomodulateurs
|
US5286746A
(en)
*
|
1991-12-20 |
1994-02-15 |
E. R. Squibb & Sons, Inc. |
Sulfur-substituted mevinic acid derivatives
|
US5620876A
(en)
*
|
1992-04-29 |
1997-04-15 |
E. R. Squibb & Sons, Inc. |
Enzymatic hydrolysis and esterification processes for the preparation of HMG-CoA reductase inhibitors and intermediates thereof
|
ZA933359B
(en)
|
1992-05-15 |
1993-12-08 |
Sankyo Co |
Octahydronaphthalene oxime derivatives for cholesterol biosynthesis inhibition, their preparation and use
|
US5369123A
(en)
*
|
1992-10-09 |
1994-11-29 |
E. R. Squibb & Sons, Inc. |
Nitrogen-substituted mevinic acid derivatives useful as HMG-CoA reductase inhibitors
|
US6190894B1
(en)
|
1993-03-19 |
2001-02-20 |
The Regents Of The University Of California |
Method and compositions for disrupting the epithelial barrier function
|
US5409820A
(en)
*
|
1993-08-06 |
1995-04-25 |
Apotex, Inc. |
Process for the production of lovastatin using Coniothyrium fuckelii
|
US6043064A
(en)
*
|
1993-10-22 |
2000-03-28 |
Bristol-Myers Squibb Company |
Enzymatic hydroxylation process for the preparation of HMG-CoA reductase inhibitors and intermediates thereof
|
WO1995013063A1
(fr)
*
|
1993-11-09 |
1995-05-18 |
Merck & Co., Inc. |
Inhibiteurs de l'hmg-coa reductase dans la normalisation des troubles de l'endothelium vasculaire
|
US6369103B1
(en)
*
|
1994-01-18 |
2002-04-09 |
Bristol-Myers Squibb Company |
Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
|
US6268392B1
(en)
|
1994-09-13 |
2001-07-31 |
G. D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
|
US6262277B1
(en)
*
|
1994-09-13 |
2001-07-17 |
G.D. Searle And Company |
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
US6642268B2
(en)
|
1994-09-13 |
2003-11-04 |
G.D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
|
US5942423A
(en)
*
|
1995-06-07 |
1999-08-24 |
Massachusetts Institute Of Technology |
Conversion of compactin to pravastatin by actinomadura
|
NZ280074A
(en)
*
|
1995-09-21 |
1997-05-26 |
Apotex Inc Substituted For Sco |
"compactin" produced by penicillium adametzioides g smith
|
US5763653A
(en)
*
|
1997-03-13 |
1998-06-09 |
Ranbaxy Laboratories, Ltd. |
Key intermediates in the manufacture of simvastatin
|
KR100186758B1
(ko)
|
1996-08-09 |
1999-04-01 |
영진약품공업 주식회사 |
프라바스타틴(pravastatin)전구체의제조방법
|
US6046022A
(en)
*
|
1996-09-30 |
2000-04-04 |
Peking University |
Methods and compositions employing red rice fermentation products
|
US7238348B2
(en)
*
|
1996-09-30 |
2007-07-03 |
Beijing Peking University Wbl Corporation Ltd. |
Method of treatment of osteoporosis with compositions of red rice fermentation products
|
US5763646A
(en)
*
|
1997-03-13 |
1998-06-09 |
Ranbaxy Laboratories, Ltd. |
Process for manufacturing simvastatin from lovastatin or mevinolinic acid
|
EP1024804A4
(fr)
*
|
1997-05-01 |
2001-03-21 |
Bristol Myers Squibb Co |
Combinaisons therapeutiques d'inhibiteur de mtp et de vitamine liposoluble destinees a reduire les taux de lipides seriques
|
US20010006644A1
(en)
|
1997-07-31 |
2001-07-05 |
David J. Bova |
Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
|
GT199800127A
(es)
|
1997-08-29 |
2000-02-01 |
|
Combinaciones terapeuticas.
|
US6177121B1
(en)
|
1997-09-29 |
2001-01-23 |
Purdue Research Foundation |
Composition and method for producing low cholesterol eggs
|
US6147109A
(en)
*
|
1997-10-14 |
2000-11-14 |
The General Hospital Corporation |
Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
|
US6083497A
(en)
*
|
1997-11-05 |
2000-07-04 |
Geltex Pharmaceuticals, Inc. |
Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
|
US20080275104A1
(en)
*
|
1997-11-25 |
2008-11-06 |
Musc Foundation For Research Development |
Methods of treating juvenile type 1 diabetes mellitus
|
US6180597B1
(en)
|
1998-03-19 |
2001-01-30 |
Brigham And Women's Hospital, Inc. |
Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
|
US20030078211A1
(en)
*
|
1998-06-24 |
2003-04-24 |
Merck & Co., Inc. |
Compositions and methods for inhibiting bone resorption
|
EP1088333A4
(fr)
|
1998-06-24 |
2005-08-10 |
Merck & Co Inc |
Compositions et procedes inhibant la resorption osseuse
|
US6423751B1
(en)
|
1998-07-14 |
2002-07-23 |
The Brigham And Women's Hospital, Inc. |
Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
|
IL141786A0
(en)
|
1998-09-17 |
2002-03-10 |
Bristol Myers Squibb Co |
A pharmaceutical composition for treating diabetes containing an ap2 inhibitor
|
SK288117B6
(sk)
|
1998-11-20 |
2013-09-03 |
Skyepharma Canada Inc. |
Rapidly dispersing solid dry therapeutic dosage form
|
DK1140190T3
(da)
|
1998-12-23 |
2002-12-23 |
Searle Llc |
Kombinationer af ileumgaldesyretransport-inhibitorer og galdesyre-sekvestreringsmidler til cardiovaskulære indikatorer
|
NZ512534A
(en)
|
1998-12-23 |
2003-11-28 |
G |
Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
|
IL143944A0
(en)
*
|
1998-12-23 |
2002-04-21 |
Searle Llc |
Combinations for cardiovascular indications
|
NZ512537A
(en)
|
1998-12-23 |
2003-11-28 |
G |
Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
|
BR9916486A
(pt)
*
|
1998-12-23 |
2002-02-05 |
Searle Llc |
Combinações de inibidores do transporte de ácidos biliares no ìleo e inibidores da proteìna de transferência do ester colesteril para indicações cardiovasculares
|
EP1140184B1
(fr)
*
|
1998-12-23 |
2003-06-04 |
G.D. Searle LLC. |
Combinaisons d'inhibiteurs de la proteine de transfert du cholesteryle-ester et de derives de l'acide nicotinique utilisees dans le cadre de troubles cardio-vasculaires
|
PT1140185E
(pt)
|
1998-12-23 |
2003-10-31 |
Searle Llc |
Combinacoes de inibidores de proteina de transferencia de ester de colesterilo com agentes sequestrantes de acido biliar para indicacoes cardiovasculares
|
WO2000038722A1
(fr)
|
1998-12-23 |
2000-07-06 |
G.D. Searle & Co. |
COMBINAISONS D'INHIBITEURS DE LA PROTEINE DE TRANSFERT DE L'ESTER DE CHOLESTERYLE ET D'INHIBITEURS DE LA HMG CoA-REDUCTASE UTILISEES DANS LE CADRE DE TROUBLES CARDIO-VASCULAIRES
|
US6323021B1
(en)
*
|
1999-01-15 |
2001-11-27 |
Industrial Technology Research Institute |
Mutant strain of penicillium citrinum and use thereof for preparation of compactin
|
SE9903028D0
(sv)
*
|
1999-08-27 |
1999-08-27 |
Astra Ab |
New use
|
WO2001015674A2
(fr)
*
|
1999-08-30 |
2001-03-08 |
Aventis Pharma Deutschland Gmbh |
Utilisation d'inhibiteurs du systeme renine-angiotensine dans la prevention de manifestations cardio-vasculaires
|
CO5251465A1
(es)
*
|
2000-01-26 |
2003-02-28 |
Pfizer Prod Inc |
Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
|
CZ20022779A3
(cs)
|
2000-02-24 |
2003-02-12 |
Biogal Gyogyszergyar Rt. |
Způsob purifikace fermentačního bujónu
|
US6395767B2
(en)
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
WO2001068637A2
(fr)
|
2000-03-10 |
2001-09-20 |
Pharmacia Corporation |
Procede de preparation de tetrahydrobenzothiepines
|
WO2001068096A2
(fr)
*
|
2000-03-10 |
2001-09-20 |
Pharmacia Corporation |
Polytherapie pour la prophylaxie et le traitement d'etats et de troubles hyperlipidemiques
|
WO2001081611A1
(fr)
*
|
2000-04-27 |
2001-11-01 |
Biocon India Limited |
Nouveau procede de fabrication et de purification de compactine
|
DE10030375A1
(de)
*
|
2000-06-21 |
2002-01-03 |
Bayer Ag |
Verwendung von MTP-Inhibitoren zur Senkung von ppTRL
|
US8586094B2
(en)
|
2000-09-20 |
2013-11-19 |
Jagotec Ag |
Coated tablets
|
SK4112003A3
(en)
*
|
2000-10-12 |
2004-01-08 |
Nissan Chemical Ind Ltd |
Preventives and remedies for complications of diabetes
|
ATE318272T1
(de)
|
2001-04-11 |
2006-03-15 |
Bristol Myers Squibb Co |
Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren
|
WO2003000239A1
(fr)
*
|
2001-06-21 |
2003-01-03 |
Andrx Pharmaceuticals, Inc. |
Compositions pharmaceutiques stables a base de pravastatine
|
US20040077625A1
(en)
*
|
2001-07-25 |
2004-04-22 |
Tremont Samuel J. |
Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
|
US7238671B2
(en)
*
|
2001-10-18 |
2007-07-03 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
KR20040054729A
(ko)
*
|
2001-10-18 |
2004-06-25 |
브리스톨-마이어스 스큅 컴퍼니 |
인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도
|
US6806381B2
(en)
*
|
2001-11-02 |
2004-10-19 |
Bristol-Myers Squibb Company |
Process for the preparation of aniline-derived thyroid receptor ligands
|
JP2005518347A
(ja)
*
|
2001-11-02 |
2005-06-23 |
ジー.ディー. サール エルエルシー |
頂端ナトリウム共依存性胆汁酸輸送(asbt)およびタウロコール酸塩取り込みの阻害剤としての新規一および二フッ化ベンゾチエピン化合物
|
US20040142902A1
(en)
*
|
2001-11-08 |
2004-07-22 |
Struijker- Boudier Harry A.J. |
Implant dosage form and use thereof for the delivery of a cholosterol lowering agent
|
EP1443919A4
(fr)
*
|
2001-11-16 |
2006-03-22 |
Bristol Myers Squibb Co |
Inhibiteurs doubles de la proteine de liaison des acides gras des adipocytes et de la proteine de liaison des acides gras des keratinocytes
|
US6831102B2
(en)
*
|
2001-12-07 |
2004-12-14 |
Bristol-Myers Squibb Company |
Phenyl naphthol ligands for thyroid hormone receptor
|
CA2471639A1
(fr)
|
2002-01-17 |
2003-07-31 |
Pharmacia Corporation |
Nouveaux composes d'alkyl/aryl hydroxy ou cetothiepine servant d'inhibiteurs du transport des acides biliaires de type ileal et de l'absorption de taurocholate
|
KR100379075B1
(en)
*
|
2002-03-07 |
2003-04-08 |
Jinis Biopharmaceuticals Co |
Method for producing low cholesterol animal food product and food product therefrom
|
AU2003225102A1
(en)
*
|
2002-04-23 |
2003-11-10 |
Bristol-Myers Squibb Company |
Modified-release vasopeptidase inhibitor formulation, combinations and method
|
WO2003094845A2
(fr)
|
2002-05-08 |
2003-11-20 |
Bristol-Myers Squibb Company |
Ligands du recepteur de la thyroide a base de pyridine
|
JP4478563B2
(ja)
*
|
2002-05-14 |
2010-06-09 |
プレゼント インヴェストメンツ エルエルシー |
送信信号の形成方法
|
US7057046B2
(en)
*
|
2002-05-20 |
2006-06-06 |
Bristol-Myers Squibb Company |
Lactam glycogen phosphorylase inhibitors and method of use
|
JP2006503023A
(ja)
*
|
2002-09-03 |
2006-01-26 |
バイオヴェイル ラボラトリーズ インコーポレイテッド |
スタチン薬物の放出調節ための医薬品製剤および方法
|
US20060019269A1
(en)
*
|
2002-10-17 |
2006-01-26 |
Decode Genetics, Inc. |
Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
|
US20080293750A1
(en)
*
|
2002-10-17 |
2008-11-27 |
Anna Helgadottir |
Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
|
ES2344057T3
(es)
*
|
2002-10-23 |
2010-08-17 |
Bristol-Myers Squibb Company |
Inhibidores de la dipeptidil peptidasa iv basados en nitrilos de glicina.
|
US7098235B2
(en)
*
|
2002-11-14 |
2006-08-29 |
Bristol-Myers Squibb Co. |
Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
|
JP2006513186A
(ja)
|
2002-12-20 |
2006-04-20 |
ファイザー・プロダクツ・インク |
Cetp阻害剤およびhmg−coaレダクターゼ阻害剤を含む剤形
|
US20040132771A1
(en)
*
|
2002-12-20 |
2004-07-08 |
Pfizer Inc |
Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
|
JP2006516620A
(ja)
*
|
2003-01-24 |
2006-07-06 |
ブリストル−マイヤーズ スクイブ カンパニー |
甲状腺受容体におけるシクロアルキル含有アニリドリガンド
|
TW200504021A
(en)
*
|
2003-01-24 |
2005-02-01 |
Bristol Myers Squibb Co |
Substituted anilide ligands for the thyroid receptor
|
US7557143B2
(en)
*
|
2003-04-18 |
2009-07-07 |
Bristol-Myers Squibb Company |
Thyroid receptor ligands
|
US20040248972A1
(en)
*
|
2003-05-16 |
2004-12-09 |
Ambit Biosciences Corporation |
Compounds and uses thereof
|
US20050182125A1
(en)
*
|
2003-05-16 |
2005-08-18 |
Ambit Biosciences Corporation |
Pyrrole compounds and uses thereof
|
EP1636183A1
(fr)
*
|
2003-05-16 |
2006-03-22 |
Ambit Biosciences Corporation |
Composes pyrroliques et leurs utilisations
|
US7459474B2
(en)
*
|
2003-06-11 |
2008-12-02 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
JP2007531697A
(ja)
*
|
2003-07-11 |
2007-11-08 |
プロ−ファーマシューティカルズ,インコーポレイティド |
疎水性薬剤のデリバリーのための組成物と方法
|
US6995183B2
(en)
*
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7250444B2
(en)
*
|
2003-08-11 |
2007-07-31 |
Pfizer Inc. |
Pyrrole-based HMG-CoA reductase inhibitors
|
EP1510208A1
(fr)
|
2003-08-22 |
2005-03-02 |
Fournier Laboratories Ireland Limited |
Compositions pharmaceutiques comprenant une combinaison de metformine et de statine
|
US20050053664A1
(en)
*
|
2003-09-08 |
2005-03-10 |
Eliezer Zomer |
Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
|
US7317109B2
(en)
*
|
2003-11-12 |
2008-01-08 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
WO2005047297A1
(fr)
*
|
2003-11-12 |
2005-05-26 |
Phenomix Corporation |
Composés heterocycliques d'acide boronique
|
US7767828B2
(en)
*
|
2003-11-12 |
2010-08-03 |
Phenomix Corporation |
Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7576121B2
(en)
*
|
2003-11-12 |
2009-08-18 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
WO2005051298A2
(fr)
|
2003-11-19 |
2005-06-09 |
Metabasis Therapeutics, Inc. |
Nouvelles substances thyromimetiques contenant du phosphore
|
EP1722780A4
(fr)
*
|
2003-11-26 |
2008-12-17 |
Univ Duke |
Technique de prevention ou de traitement du glaucome
|
BRPI0417138A
(pt)
*
|
2003-12-05 |
2007-02-21 |
Warner Lambert Co |
n-alquil-pirroles como inibidores de hmg-coa-redutase
|
WO2005063294A1
(fr)
|
2003-12-30 |
2005-07-14 |
Kowa Company, Ltd. |
Inhibiteur de formation de complexe $g(g)-secretase
|
US20070161700A1
(en)
*
|
2004-12-28 |
2007-07-12 |
Kowa Company, Ltd. |
Inhibitor for the formation of y-secretase complex
|
US8158362B2
(en)
*
|
2005-03-30 |
2012-04-17 |
Decode Genetics Ehf. |
Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
|
US20100216863A1
(en)
*
|
2004-01-30 |
2010-08-26 |
Decode Genetics Ehf. |
Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
|
WO2005079314A2
(fr)
*
|
2004-02-13 |
2005-09-01 |
Pro-Pharmaceuticals, Inc. |
Compositions et procedes utilises pour traiter l'acne et la candida
|
JP4728226B2
(ja)
|
2004-02-25 |
2011-07-20 |
興和株式会社 |
Cdc42タンパク質の核内移行促進剤及びそのスクリーニング方法
|
WO2005079846A1
(fr)
|
2004-02-25 |
2005-09-01 |
Kowa Company, Ltd. |
AGENT PROMOTEUR DE TRANSFERT NUCLÉAIRE POUR LA PROTÉINE Rac ET MÉTHODE POUR LA CRIBLER
|
ES2239533B1
(es)
*
|
2004-03-01 |
2006-12-16 |
Ercros Industrial, S.A. |
Procedimiento para la obtencion de compactina.
|
WO2005087234A1
(fr)
|
2004-03-05 |
2005-09-22 |
The Trustees Of The University Of Pennsylvania |
Traitement a faibles effets secondaires contre des affections liees a l'hyperlipidemie et l'hypercholesterolemie
|
US7262318B2
(en)
*
|
2004-03-10 |
2007-08-28 |
Pfizer, Inc. |
Substituted heteroaryl- and phenylsulfamoyl compounds
|
US20060211752A1
(en)
|
2004-03-16 |
2006-09-21 |
Kohn Leonard D |
Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
|
EP1734819A1
(fr)
*
|
2004-03-19 |
2006-12-27 |
Pro-Pharmaceuticals, Inc. |
Compositions et methodes permettant de cibler des tumeurs metastatiques a l'aide de polymeres multivalents carbohydrates lies a un ligand
|
KR100598326B1
(ko)
|
2004-04-10 |
2006-07-10 |
한미약품 주식회사 |
HMG-CoA 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
|
US20050288340A1
(en)
*
|
2004-06-29 |
2005-12-29 |
Pfizer Inc |
Substituted heteroaryl- and phenylsulfamoyl compounds
|
TW200611704A
(en)
*
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
US7145040B2
(en)
*
|
2004-07-02 |
2006-12-05 |
Bristol-Myers Squibb Co. |
Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
|
US7534763B2
(en)
|
2004-07-02 |
2009-05-19 |
Bristol-Myers Squibb Company |
Sustained release GLP-1 receptor modulators
|
US7786163B2
(en)
*
|
2004-07-12 |
2010-08-31 |
Forest Laboratories Holdings Limited (BM) |
Constrained cyano compounds
|
US7572805B2
(en)
|
2004-07-14 |
2009-08-11 |
Bristol-Myers Squibb Company |
Pyrrolo(oxo)isoquinolines as 5HT ligands
|
US20110217412A1
(en)
*
|
2004-07-30 |
2011-09-08 |
Jinis Biopharmaceuticals Co. |
Cholesterol lowering supplement and low cholesterol egg produced by using the same
|
KR100637762B1
(ko)
*
|
2004-07-30 |
2006-10-23 |
주식회사 지니스 |
저콜레스테롤 란을 생산하기 위한 가금류용 사료첨가제 및 이를 이용한 저콜레스테롤 란의 생산방법
|
EP1773128A2
(fr)
*
|
2004-08-02 |
2007-04-18 |
Pro-Pharmaceuticals, Inc. |
Compositions et procedes permettant d'ameliorer l'efficacite d'une chimiotherapie a l'aide de cytotoxines microbiennes
|
AR051446A1
(es)
*
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
US7517991B2
(en)
*
|
2004-10-12 |
2009-04-14 |
Bristol-Myers Squibb Company |
N-sulfonylpiperidine cannabinoid receptor 1 antagonists
|
US7635699B2
(en)
*
|
2004-12-29 |
2009-12-22 |
Bristol-Myers Squibb Company |
Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7589088B2
(en)
*
|
2004-12-29 |
2009-09-15 |
Bristol-Myers Squibb Company |
Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
WO2006076597A1
(fr)
*
|
2005-01-12 |
2006-07-20 |
Bristol-Myers Squibb Company |
Heterocycles bicycliques constituant des modulateurs des recepteurs cannabinoides
|
US7220859B2
(en)
|
2005-01-12 |
2007-05-22 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
US7314882B2
(en)
*
|
2005-01-12 |
2008-01-01 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
US20060160850A1
(en)
*
|
2005-01-18 |
2006-07-20 |
Chongqing Sun |
Bicyclic heterocycles as cannabinoid receptor modulators
|
US7238702B2
(en)
*
|
2005-02-10 |
2007-07-03 |
Bristol-Myers Squibb Company |
Dihydroquinazolinones as 5HT modulators
|
US20070293535A1
(en)
*
|
2005-02-24 |
2007-12-20 |
Kowa Company, Ltd. |
Nuclear Transfer Promoter for Ddc42 Protein and Method of Screening the Dame
|
US20060235028A1
(en)
|
2005-04-14 |
2006-10-19 |
Li James J |
Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
|
US7521557B2
(en)
|
2005-05-20 |
2009-04-21 |
Bristol-Myers Squibb Company |
Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7825139B2
(en)
*
|
2005-05-25 |
2010-11-02 |
Forest Laboratories Holdings Limited (BM) |
Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US20060275356A1
(en)
*
|
2005-05-25 |
2006-12-07 |
Burgess James W |
Pharmaceutical compositions for treating or preventing coronary artery disease
|
CN101282991A
(zh)
*
|
2005-05-26 |
2008-10-08 |
布里斯托尔-迈尔斯斯奎布公司 |
N-端修饰的胰高血糖素样肽-1受体调节剂
|
US7572808B2
(en)
*
|
2005-06-17 |
2009-08-11 |
Bristol-Myers Squibb Company |
Triazolopyridine cannabinoid receptor 1 antagonists
|
US7632837B2
(en)
*
|
2005-06-17 |
2009-12-15 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid-1 receptor modulators
|
US7629342B2
(en)
*
|
2005-06-17 |
2009-12-08 |
Bristol-Myers Squibb Company |
Azabicyclic heterocycles as cannabinoid receptor modulators
|
US7452892B2
(en)
*
|
2005-06-17 |
2008-11-18 |
Bristol-Myers Squibb Company |
Triazolopyrimidine cannabinoid receptor 1 antagonists
|
US7317012B2
(en)
*
|
2005-06-17 |
2008-01-08 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoind-1 receptor modulators
|
US20060287342A1
(en)
*
|
2005-06-17 |
2006-12-21 |
Mikkilineni Amarendra B |
Triazolopyrimidine heterocycles as cannabinoid receptor modulators
|
US7795436B2
(en)
*
|
2005-08-24 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
|
EP1919393A2
(fr)
*
|
2005-09-01 |
2008-05-14 |
Prescient Medical, Inc. |
Medicaments enrobant un dispositif destine a traiter une plaque vulnerable
|
WO2007035395A2
(fr)
*
|
2005-09-16 |
2007-03-29 |
Virginia Commonwealth University Intellectual Property Foundation |
Compositions therapeutiques comprenant des gonadotropines chorioniques et des inhibiteurs de la reductase hmg coa
|
WO2007047880A2
(fr)
*
|
2005-10-18 |
2007-04-26 |
Aegerion Pharmaceuticals |
Methodes de traitement de troubles associees l'hyperlipidemie chez un mammifere
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
AR056155A1
(es)
*
|
2005-10-26 |
2007-09-19 |
Bristol Myers Squibb Co |
Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
|
EP1943215A2
(fr)
|
2005-10-31 |
2008-07-16 |
Brystol-Myers Squibb Company |
Inhibiteurs à base d amide et de bêta-amino de pyrrolidinyle de la dipeptidyl peptidase iv et procédés
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
US7592461B2
(en)
|
2005-12-21 |
2009-09-22 |
Bristol-Myers Squibb Company |
Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
EP1976873A2
(fr)
*
|
2006-01-11 |
2008-10-08 |
Brystol-Myers Squibb Company |
Modulateurs de peptides 1 de type glucagon humain et leur utilisation pour traiter le diabète et des états associés
|
US7553836B2
(en)
|
2006-02-06 |
2009-06-30 |
Bristol-Myers Squibb Company |
Melanin concentrating hormone receptor-1 antagonists
|
CA2569776A1
(fr)
*
|
2006-02-17 |
2007-08-17 |
Kos Life Sciences, Inc. |
Formulation de niacine provoquant de faibles symptomes de bouffee congestive
|
US20090069275A1
(en)
*
|
2006-02-17 |
2009-03-12 |
Rocca Jose G |
Low flush niacin formulation
|
US20070238770A1
(en)
*
|
2006-04-05 |
2007-10-11 |
Bristol-Myers Squibb Company |
Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
|
US20070269503A1
(en)
*
|
2006-05-16 |
2007-11-22 |
James Walter Burgess |
Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof
|
WO2007139589A1
(fr)
|
2006-05-26 |
2007-12-06 |
Bristol-Myers Squibb Company |
Modulateurs des récepteurs de glp-1 à libération prolongée
|
US7919598B2
(en)
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
US20080044326A1
(en)
*
|
2006-07-04 |
2008-02-21 |
Esencia Co., Ltd. |
Sterilizer for baby products
|
US7795291B2
(en)
|
2006-07-07 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
|
US7727978B2
(en)
|
2006-08-24 |
2010-06-01 |
Bristol-Myers Squibb Company |
Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
|
WO2008057862A2
(fr)
|
2006-11-01 |
2008-05-15 |
Bristol-Myers Squibb Company |
Modulateurs de récepteur de glucocorticoïde, d'activité ap-1 et/ou nf-κb, et leur utilisation
|
WO2008059466A1
(fr)
*
|
2006-11-17 |
2008-05-22 |
Ranbaxy Laboratories Limited |
Production de compactine au moyen d'une nouvelle souche mutante de penicillium citrinum atcc 38065
|
EP2120927A1
(fr)
*
|
2006-12-21 |
2009-11-25 |
Aegerion Pharmaceuticals, Inc. |
Procédés de traitement de l'obésité à l'aide d'une combinaison comprenant un inhibiteur de mtp et un inhibiteur de l'absorption du cholestérol
|
EP2114151A4
(fr)
*
|
2007-03-01 |
2010-03-17 |
Concourse Health Sciences Llc |
Isomères de niacinate d'inositol et utilisations de ceux-ci
|
AR065670A1
(es)
|
2007-03-09 |
2009-06-24 |
Indigene Pharmaceuticals Inc |
Combinacion de metformina r-(+) lipoato y agentes antihiperlipidemicos para el tratamiento de hiperglucemia diabetica y complicaciones diabeticas
|
US20080227846A1
(en)
*
|
2007-03-13 |
2008-09-18 |
Musc Foundation For Research Development |
Methods of treating juvenile type 1 diabetes mellitus
|
PE20090185A1
(es)
|
2007-03-22 |
2009-02-28 |
Bristol Myers Squibb Co |
Formulaciones farmaceuticas que contienen un inhibidor sglt2
|
CN101687873A
(zh)
|
2007-04-17 |
2010-03-31 |
百时美施贵宝公司 |
具有稠合杂环的11β-羟基类固醇Ⅰ型脱氢酶抑制剂
|
PE20090696A1
(es)
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
EP2147008A2
(fr)
*
|
2007-05-18 |
2010-01-27 |
Bristol-Myers Squibb Company |
Structures cristallines des inhibiteurs de sglt-2 et procédés pour leur préparation
|
EP2581081A3
(fr)
|
2007-06-01 |
2013-07-31 |
The Trustees Of Princeton University |
Traitement d'infections virales par modulation de voies métaboliques de cellules hôtes
|
US20090011994A1
(en)
*
|
2007-07-06 |
2009-01-08 |
Bristol-Myers Squibb Company |
Non-basic melanin concentrating hormone receptor-1 antagonists and methods
|
JP2010534722A
(ja)
*
|
2007-07-27 |
2010-11-11 |
ブリストル−マイヤーズ スクイブ カンパニー |
新規グルコキナーゼ活性化薬およびその使用方法
|
JOP20080381B1
(ar)
*
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
BRPI0817211A2
(pt)
*
|
2007-09-20 |
2017-05-16 |
Irm Llc |
composto composições como moduladores da atividade de gpr119
|
EP2209780B1
(fr)
|
2007-11-01 |
2014-01-01 |
Bristol-Myers Squibb Company |
Composes non steroïdiens utiles en tant que modulateurs de l'activite ap-1 et/ou nf- b du recepteur des glucocorticoïdes et leur utilisation
|
PE20091928A1
(es)
*
|
2008-05-29 |
2009-12-31 |
Bristol Myers Squibb Co |
Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
|
ES2330184B1
(es)
|
2008-06-03 |
2010-07-05 |
Neuron Biopharma, S.A. |
Uso de estatinas como anticonvulsivantes, antiepilepticos y neuroprotectores.
|
US20120046364A1
(en)
|
2009-02-10 |
2012-02-23 |
Metabasis Therapeutics, Inc. |
Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
|
WO2010111665A1
(fr)
|
2009-03-27 |
2010-09-30 |
Bristol-Myers Squibb Company |
Procédés destinés à prévenir des événements cardiovasculaires indésirables majeurs par des inhibiteurs de la dpp-iv
|
WO2011014520A2
(fr)
|
2009-07-29 |
2011-02-03 |
Irm Llc |
Composés et compositions pouvant servir de modulateurs de l'activité du gpr119
|
KR20120092629A
(ko)
|
2009-10-09 |
2012-08-21 |
아이알엠 엘엘씨 |
Gpr119 활성의 조절제로서의 화합물 및 조성물
|
EP2498757A1
(fr)
|
2009-11-13 |
2012-09-19 |
Bristol-Myers Squibb Company |
Formulations de metformine a masse reduite
|
HUE040486T2
(hu)
|
2009-11-13 |
2019-03-28 |
Astrazeneca Ab |
Kétrétegû tabletta készítmények
|
CA2780941C
(fr)
|
2009-11-13 |
2018-06-12 |
Bristol-Myers Squibb Company |
Formulations pour comprimes a liberation immediate
|
US8394858B2
(en)
|
2009-12-03 |
2013-03-12 |
Novartis Ag |
Cyclohexane derivatives and uses thereof
|
AR079336A1
(es)
*
|
2009-12-11 |
2012-01-18 |
Irm Llc |
Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
|
TWI562775B
(en)
|
2010-03-02 |
2016-12-21 |
Lexicon Pharmaceuticals Inc |
Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
|
US8592396B2
(en)
|
2010-04-14 |
2013-11-26 |
Bristol-Myers Squibb Company |
Glucokinase activators and methods of using same
|
AU2011276254B2
(en)
|
2010-07-09 |
2016-11-03 |
James Trinca Green |
Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin
|
US8697739B2
(en)
|
2010-07-29 |
2014-04-15 |
Novartis Ag |
Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
|
JPWO2012046772A1
(ja)
|
2010-10-06 |
2014-02-24 |
国立大学法人 東京大学 |
リンパ浮腫予防治療剤
|
TWI631963B
(zh)
|
2011-01-05 |
2018-08-11 |
雷西肯製藥股份有限公司 |
包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
|
EP2797641B1
(fr)
|
2011-12-29 |
2019-07-10 |
Trustees Of Tufts College |
Fonctionnalisation de biomatériaux pour commander la régénération et des réponses à une inflammation
|
WO2014052619A1
(fr)
|
2012-09-27 |
2014-04-03 |
Irm Llc |
Dérivés et compositions de pipéridine comme modulateurs de l'activité de gpr119
|
NZ707859A
(en)
|
2012-11-20 |
2019-03-29 |
Lexicon Pharmaceuticals Inc |
Inhibitors of sodium glucose cotransporter 1
|
BR112015026513A2
(pt)
|
2013-04-17 |
2017-07-25 |
Pfizer |
derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
|
US9593113B2
(en)
|
2013-08-22 |
2017-03-14 |
Bristol-Myers Squibb Company |
Imide and acylurea derivatives as modulators of the glucocorticoid receptor
|
JP6536871B2
(ja)
|
2013-12-02 |
2019-07-03 |
国立大学法人京都大学 |
Fgfr3病の予防および治療剤ならびにそのスクリーニング方法
|
ES2822561T3
(es)
|
2014-09-15 |
2021-05-04 |
Univ Leland Stanford Junior |
Direccionamiento a enfermedad por aneurisma modulando las vías de fagocitosis
|
WO2016055901A1
(fr)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Composés d'amide substitué
|
ES2941387T3
(es)
|
2015-02-27 |
2023-05-22 |
Univ Leland Stanford Junior |
Terapia de combinación para el tratamiento de la ateroesclerosis
|
JP2018515082A
(ja)
|
2015-04-30 |
2018-06-14 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
代謝障害を処置するための抗ap2抗体及び抗原結合剤
|
US20200129440A1
(en)
|
2017-01-23 |
2020-04-30 |
Dong Wha Pharm. Co., Ltd. |
Complex formulation comprising hmg-coa reductase inhibitor and clopidogrel
|
ES2921205T3
(es)
|
2017-11-02 |
2022-08-19 |
Consejo Superior Investigacion |
Uso de estatinas para superar la resistencia a los antibióticos betalactámicos en especies bacterianas que sintetizan isoprenoides mediante la ruta de síntesis de mevalonato
|
BR112021000139A2
(pt)
|
2018-07-19 |
2021-04-06 |
Astrazeneca Ab |
Métodos de tratamento da hfpef empregando dapagliflozina e composições compreendendo a mesma
|
US20210299331A1
(en)
|
2018-07-19 |
2021-09-30 |
Kyoto University |
Pluripotent stem cell-derived plate-shaped cartilage and method for producing the same
|
BR112021004839A2
(pt)
|
2018-09-26 |
2021-06-08 |
Lexicon Pharmaceuticals, Inc. |
formas cristalinas de n-(1-((2-(dimetilamino)etil)amino)-2-metil-1-oxopropan-2-il)-4-(4-(2-metil-5-((2s,3r,4r,5s,6r)-3,4,5-triidróxi-6-(metiltio)tetraidro-2h-piran-2-il)benzil)fenil)butanamida e métodos de sua síntese
|
EP3900787A4
(fr)
|
2018-12-21 |
2022-02-23 |
Kyoto University |
Tissu de type cartilage à lubricine localisée, procédé pour sa production et composition le comprenant pour le traitement de lésions du cartilage articulaire
|
MX2021008533A
(es)
|
2019-01-18 |
2021-08-19 |
Astrazeneca Ab |
Inhibidores de la pcsk9 y metodos de uso de los mismos.
|
PE20220164A1
(es)
|
2019-05-27 |
2022-01-28 |
Immatics Us Inc |
Vectores viricos y uso de los mismos en terapias celulares adoptivas
|
US20230172996A1
(en)
|
2020-02-21 |
2023-06-08 |
Yoshikazu NAKAOKA |
Composition for alleviating pulmonary hypertension, method for predicting prognosis of pulmonary hypertension, method for assisting in determining severity of pulmonary hypertension, and method for assisting in diagnosing pulmonary hypertension
|
DE102020111571A1
(de)
|
2020-03-11 |
2021-09-16 |
Immatics US, Inc. |
Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
|
US20220023252A1
(en)
|
2020-07-27 |
2022-01-27 |
Astrazeneca Ab |
Methods of treating chronic kidney disease with dapagliflozin
|
WO2022040631A1
(fr)
|
2020-08-21 |
2022-02-24 |
Immatics US, Inc. |
Procédés d'isolement de lymphocytes t sélectionnés cd8+
|
WO2023144722A1
(fr)
|
2022-01-26 |
2023-08-03 |
Astrazeneca Ab |
Dapagliflozine destinée à être utilisée dans le traitement du prédiabète ou pour réduire le risque de développer un diabète de type 2
|